Our ingestible technologies show promising results that could transform clinical diagnostics and therapeutics for GI disease. Read more about the difficulties in diagnosing GI disease and how our technology is an expected solution.
Current methods for sampling the gut make it difficult for healthcare providers to accurately diagnose and monitor gastrointestinal diseases. Even after diagnosis, drug therapy presents a number of challenges, including achieving the most effective therapeutic dose at the site of disease.
Two meta-analyses presented by Progenity at the 2019 American College of Gastroenterology (ACG) meeting show significant limitations to current diagnostics for small intestine bacterial overgrowth (SIBO) and support the need for novel tools.